Comparison of bovine serum albumin glycation by ribose and fructose in vitro and in vivo

doi:10.1016/j.bbadis.2021.166283

PSYCH OpenIR

	Comparison of bovine serum albumin glycation by ribose and fructose in vitro and in vivo
	Mou, Lixian 1,2,4,5,6; Hu, Pingdong 2; Cao, Xiao 1,2; Chen, Yue 4,5,6; Xu, Yong 1; He, Tao 1; Wei, Yan 2; He, Rongqiao 1,2,3
通讯作者	Wei, Yan(yanwei@ibp.ac.cn) ; He, Rongqiao(herq@ibp.ac.cn)
摘要	Advanced glycation end products (AGEs) play a critical pathogenic role in the development of diabetic complications. Recent studies have shown that diabetes is associated with not only abnormal glucose metabolism but also abnormal ribose and fructose metabolism, although glucose is present at the highest concentration in humans. The glycation ability and contribution of ribose and fructose to diabetic complications remain unclear. Here, the glycation ability of ribose, fructose and glucose under a mimic physiological condition, in which the concentration of ribose or fructose was one-fiftieth that of glucose, was compared. Bovine serum albumin (BSA) was used as the working protein in our experiments. Ribose generated more AGEs and was markedly more cytotoxic to SH-SY5Y cells than fructose. The first-order rate constant of ribose glycation was found to be significantly greater than that of fructose glycation. LC-MS/MS analysis revealed 41 ribose-glycated Lys residues and 12 fructose-glycated residues. Except for the shared Lys residues, ribose reacted selectively with 17 Lys, while no selective Lys was found in fructose-glycated BSA. Protein conformational changes suggested that ribose glycation may induce BSA into amyloid-like monomers compared with fructose glycation. The levels of serum ribose were correlated positively with glycated serum protein (GSP) and diabetic duration in type 2 diabetes mellitus (T2DM), respectively. These results indicate that ribose has a greater glycation ability than fructose, while ribose largely contributes to the production of AGEs and provides a new insight to understand in the occurrence and development of diabetes complications.
关键词	Ribose Fructose Glycation Monomer Cytotoxic Type 2 diabetes mellitus
	2022
语种	英语
DOI	10.1016/j.bbadis.2021.166283
发表期刊	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
ISSN	0925-4439
卷号	1868 期号:1 页码:13
收录类别	SCI
资助项目	National Natural Science Foundation of China[NSFC 31670805] ; National Natural Science Foundation of China[31270868]
出版者	ELSEVIER
WOS关键词	NONENZYMATIC GLYCATION ; END-PRODUCTS ; TISSUE PROTEINS ; BINDING ; GLUCOSE ; ANS ; IDENTIFICATION ; GLYCOXIDATION ; HYPERTENSION ; SURFACE
WOS研究方向	Biochemistry & Molecular Biology ; Biophysics ; Cell Biology
WOS类目	Biochemistry & Molecular Biology ; Biophysics ; Cell Biology
WOS记录号	WOS:000710122800006
资助机构	National Natural Science Foundation of China
引用统计
文献类型	期刊论文
条目标识符	http://ir.psych.ac.cn/handle/311026/40881
通讯作者	Wei, Yan; He, Rongqiao
作者单位	1.Southwest Med Univ, Basic Coll Med, Luzhou 646000, Sichuan, Peoples R China 2.Univ Chinese Acad Sci, Inst Biophys, State Key Lab Brain & Cognit Sci, 15 Datun Rd, Beijing 100101, Peoples R China 3.Univ Chinese Acad Sci, Inst Psychol, CAS Key Lab Mental Hlth, Beijing 100101, Peoples R China 4.Southwest Med Univ, Affiliated Hosp, Dept Nucl Med, 25 Taiping St, Luzhou 646000, Sichuan, Peoples R China 5.Nucl Med & Mol Imaging Key Lab Sichuan Prov, Luzhou 646000, Sichuan, Peoples R China 6.Academician Expert Workstn Sichuan Prov, Luzhou 646000, Sichuan, Peoples R China
推荐引用方式 GB/T 7714	Mou, Lixian,Hu, Pingdong,Cao, Xiao,et al. Comparison of bovine serum albumin glycation by ribose and fructose in vitro and in vivo[J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE,2022,1868(1):13.
APA	Mou, Lixian.,Hu, Pingdong.,Cao, Xiao.,Chen, Yue.,Xu, Yong.,...&He, Rongqiao.(2022).Comparison of bovine serum albumin glycation by ribose and fructose in vitro and in vivo.BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE,1868(1),13.
MLA	Mou, Lixian,et al."Comparison of bovine serum albumin glycation by ribose and fructose in vitro and in vivo".BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE 1868.1(2022):13.